Clinical trials: Liver Transplant Recipient
Liver Transplantation
To Evaluate the Efficacy and Safety of ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients
This study's objective is to evaluate the incidence rate of acute rejection reactions after 24 weeks treatment with ADVAGRAF® following 3 months treatment with tacrolimus in new liver transplant recipients.
- Trial name
- NCT03423225
- Testing
- ADVAGRAF®
- Volunteers
- 31 people
- Sponsor
- Kim, Seoung-Hoon